Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and
Hello,
Hope you all had good four-day work weeks! I can feel the fall air trying to make its way into Brooklyn, but here's hoping we can hold onto summer temperatures a little longer.
On the 19th anniversary of September 11th, I'm reflecting on spending the first few months of the
Reminder that you're now seeing a different name at the top of this email — our "
Be sure to subscribe here for your daily dose of healthcare news from the Business Insider team.
Let's dive in.
AstraZeneca's experimental coronavirus vaccine hit a snag
All eyes are on the drugmakers developing
Take this week's biggest headline: Stat News on Tuesday reported that AstraZeneca's vaccine trial had been put on hold after a participant had a potential adverse event.
The participant, AstraZeneca's CEO later said, had serious neurologic symptoms, and the trial is on hold until researchers can get a better idea of what's going on. AstraZeneca hasn't said when the trial might resume.
Even with the setback, AstraZeneca's CEO said Thursday that a vaccine could be available this year.
To be sure, clinical trials are paused all the time, and whether this will have long term implications for AstraZeneca's
In the meantime — some of the vaccine developers signed a pledge to put safety before speed when developing vaccines. It's happening as people worry a vaccine might be rushed to be ready in time for the presidential election in November.
Experts aren't expecting a vaccine before the election, for what it's worth. Aria Bendix has the likely vaccine timeline, according to doctors, government officials, and analysts.
There might be trouble ahead for other vaccine frontrunners, including Moderna. This week, a top analyst predicted a 'winter of discontent' for the company. Andrew Dunn reports the three reasons the analyst thinks the stock will drop 30%.
Over the next few weeks, we'll be keeping an eye out for what's ahead for AstraZeneca's vaccine, as well as for immunizations from the other frontrunners, Moderna and Pfizer.
I found it helpful to read through analyst notes about likely scenarios for AstraZeneca's vaccine once we know more about what happened with the participant. The scenarios range from just a few weeks off schedule, to the end of the line for the experimental shot, to more serious implications for vaccine hopes.
Read the full story here>>
Wall Street analysts lay out how the unexpected pause in AstraZeneca's coronavirus vaccine trial could slow the race to halt the pandemic
Are you new to Business Insider's paywall? Use my link here to get 20% off your subscription.
Meet the 100 leaders transforming business
This week, the Business Insider newsroom pulled together a big project highlighting 100 people transforming business.
Our team got to nominate our 10 picks of people transforming healthcare. You can find this year's honorees here.
They include folks like Dr. Merit Cudkowicz, a top ALS researcher, Dr. Ted Love, the CEO of Global Blood Therapeutics, Dr. Ala Stanford (pictured), who's helping the poorest parts of Philadelphia tackle the pandemic, and more.
Kimberly Leonard has a great summary of the contributions this year's honorees from North America, Asia, and Europe made to healthcare — especially in a year defined by the coronavirus pandemic.
Read the full story here>>
The 10 people transforming healthcare in 2020
The secret club that determines the future of healthcare
Now that I'm editing more, I haven't had as much time to go as deep down reporting rabbit holes.
But this summer, I made one exception: I heard about the Employer Health Innovation Roundtable (or EHIR) for the first time in June.
I quickly realized its ability to match employers like Google and Boeing with young startups looking to break into the employer-funded healthcare market had set so many companies I've followed over the years on the path to success.
So over the past few months, I've spoken with startup and employer participants to get an inside look at how the process works and what it's led to. Here's what I learned.
Read the full story here>>
Inside the secret club that helps determine which healthcare startups blow up
A short-lived "skinny" coronavirus stimulus plan
It might be the end of the line for coronavirus stimulus hopes, at least until the election.
Kimberly this week spent time keeping tabs on Congress's latest attempt to pass a coronavirus stimulus bill.
This one, brought forth by Republican leadership in the Senate, would've included $500 billion in relief, but didn't include another round of checks. It was voted down on Thursday.
Read the full story here>>
Democrats just blocked McConnell's 'skinny' coronavirus stimulus, dimming prospects for another relief package before the presidential election
Finally, blink and you might've missed that there was a whole slew of financing developments this week among healthcare startups. Here's what you need to know:
- American Well updated its S-1 this week, setting a potential range for when it goes public, looking to raise $488.5 million. Blake Dodge has the 5 key details you need to know about the company as it gears up to go public.
- Grail, a cancer detection company backed by Jeff Bezos, filed to go public this week. Read its S-1 here.
- Truepill, a pharmacy startup that powers DTC healthcare companies just raised another $75 million. I've been following the company since its early days in 2019, and you can read more about its ambitions here.
- Grand Rounds, (whose CEO I chatted with as part of the EHIR piece!) raised another $175 million from investors including The Carlyle Group.
- AI drug discovery company Recursion Pharma raised $239 million. Here's some background on the company's ambitions from the last time they raised money about a year ago.
Plus - Zocdoc's cofounder is suing the company and claims he was pushed out in 2015 in an illegal "coup." Read on for all the details here.
Reach me at lramsey@businessinsider.com and the whole healthcare team at healthcare@businessinsider.com.
- Lydia